Lexeo Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Lexeo reported interim Phase I/II data for LX2020 in PKP2-ACM: 7 high-dose participants achieved 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and 44% mean reduction in premature ventricular contractions (PVCs) at latest assessment (data cutoff October 15, 2026); drug was generally well tolerated with no clinically significant complement activation and no study discontinuations. FDA confirmed openness to guideline-defined NSVT as a primary endpoint for accelerated approval. Pivotal study design finalization expected H1 2027; initiation targeted H2 2027. Cash position: $219.1M as of September 30, 2026, expected to fund operations into 2028.
Why this rating
Strong clinical data in rare orphan disease supports material value creation; $219M cash runway covers pivotal trial. Event is significant but subject to regulatory and execution risks in early-stage biotech.
Tradability signal
NO TRADE
No trade: already up 34.1% on the news and the fade evidence is too weak. Similar past filings (508 in this cell) moved -0.04% in the called direction over 4 hrs; shrunk for sample size that's a -0.04% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.99 ▼ 16.01% | at our read · unknown $3.56 | +10 min · unknown $4.17 ▲ 17.13% | +30 min · unknown $3.70 ▲ 3.90% | +1 hr · unknown $3.28 ▼ 7.87% | +4 hrs · unknown $3.06 ▼ 14.04% |
The stock had already moved +19.06% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.